BioSpace News Archive

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will report third quarter financial results on Thursday, November 5, 2020.

Milestone Pharmaceuticals Inc. announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor,

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it will issue its financial results for the fiscal 2020 third quarter ended September 30, 2020 on Thursday, Nov

- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, provided preliminary unaudited revenue estimates for the third quarter ended September 30, 2020 , in conjunction with proposed debt refinancing tran

Cleure, the leading clean and hypoallergenic personal care brand for sensitivities, is expanding its product line with the launch of their new Mineral SPF 30 Sunscreen. Formulated with non-micro

World renowned Biochemist, Dr. Nathan S. Bryan introduces N1o1, the first anti-aging skincare that uses a Nobel Prize winning discovery to defy aging skin by correcting the cause of wrinkled and damaged skin plus age spots and blemish prone skin